# Study in Subjects With Small Primary Choroidal Melanoma

Source: https://onco.cc/trials/nct03052127/  
OnCo record `nct03052127` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belzupacap sarotalocan run by Aura Biosciences, completed.

## Summary

Study in Subjects With Small Primary Choroidal Melanoma is a phase 1/2 interventional study registered as NCT03052127 by Aura Biosciences, with 57 participants enrolled, started 2017-02-27. Conditions recorded: Uveal Melanoma, Ocular Melanoma and Choroidal Melanoma. Interventions recorded: Light-activated AU-011 and Laser Activation.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03052127
- Phase: 1/2
- Setting: A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma
- Sponsor: Aura Biosciences
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT03052127: https://clinicaltrials.gov/study/NCT03052127

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Belzupacap sarotalocan](https://onco.cc/drugs/belzupacap-sarotalocan/)
- companies: [Aura Biosciences](https://onco.cc/companies/aura-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct03052127.json